Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Rash, Skin exfoliation, Urticaria, Vomiting
Clinical narrative: Cough; Patient hasn't received 2nd dose yet; It was red; It was inflamed.; She started with a rash 1 week after receiving 1st dose/ rash on her back that was a size of a quarter/it popped up on her knee/started behind ear and progressed to back of the neck; Nausea; Vomiting; Skin pealing; Itching; Hives; This spontaneous case was reported by a consumer and describes the occurrence of INFLAMMATION (It was inflamed.), SKIN EXFOLIATION (Skin pealing), ERYTHEMA (It was red), PRODUCT DOSE OMISSION ISSUE (Patient hasn't received 2nd dose yet) and COUGH (Cough) in a 63-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 037B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Previously administered products included for an unreported indication: METFORMIN (Hives and Diarrhea) in 2013, MORPHINE (Hives) in 2013, CRESTOR (40 milligram, Vertigo) in 2013, PHENERGAN [DIBROMPROPAMIDINE ISETIONATE;PROMETHAZINE HYDROCHLORIDE] (Hives, anxiety and Eruption) in 2013 and LISINOPRIL (Hives) in 2013. Concurrent medical conditions included Food allergy (Reaction from  fresh fish from chesterpeek Bay in verginia, tongue started to swolled went to ER in High point wake forest hospital.) since 03-Mar-2000, Asthma and Hives. Concomitant products included BUDESONIDE, FORMOTEROL FUMARATE (SYMBICORT), CETIRIZINE HYDROCHLORIDE (ZYRTEC [CETIRIZINE HYDROCHLORIDE]) and MONTELUKAST SODIUM (SINGULAIR) for an unknown indication.    On 28-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 28-Apr-2021, the patient experienced PRURITUS (Itching) and URTICARIA (Hives). On 03-May-2021, the patient experienced SKIN EXFOLIATION (Skin pealing), NAUSEA (Nausea) and VOMITING (Vomiting). On 04-May-2021, the patient experienced INFLAMMATION (It was inflamed.), ERYTHEMA (It was red) and RASH (She started with a rash 1 week after receiving 1st dose/ rash on her back that was a size of a quarter/it popped up on her knee/started behind ear and progressed to back of the neck). On 26-May-2021, the patient experienced PRODUCT DOSE OMISSION ISSUE (Patient hasn't received 2nd dose yet). On an unknown date, the patient experienced COUGH (Cough). The patient was treated with TRIAMCINOLONE ACETONIDE ongoing from 05-Apr-2021 at an unspecified dose and frequency; DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency and HYDROXYZINE at a dose of 25 UNK. At the time of the report, INFLAMMATION (It was inflamed.), SKIN EXFOLIATION (Skin pealing), ERYTHEMA (It was red), COUGH (Cough), PRURITUS (Itching), URTICARIA (Hives), RASH (She started with a rash 1 week after receiving 1st dose/ rash on her back that was a size of a quarter/it popped up on her knee/started behind ear and progressed to back of the neck), NAUSEA (Nausea) and VOMITING (Vomiting) outcome was unknown and PRODUCT DOSE OMISSION ISSUE (Patient hasn't received 2nd dose yet) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Follow up was received on 04-Aug-2021 contains significant information. Patients demographic details, medical history and  events cough, urticaria, itching were added. On 05-Aug-2021: Followup received on 05-Aug-2021, the patients DOB, weight and height was updated, past medications were added. Event vomiting was added.